Physicians' Academy for Cardiovascular Education

CV Inflammation

Inflammation is receiving increasing attention for a potential role in residual CV risk. Follow recent insights into the importance of inflammation of CVD.

Strong evidence for colchicine in patients with chronic coronary disease

5' education - Oct. 7, 2020 - Aernoud Fiolet, MD and prof. Jan Hein Cornel, MD, PhD

Lp(a) and immune metabolism

5' education - Mar. 12, 2020 - EAS-endorsed Lp(a) satellite meeting - Jeffrey Kroon, PhD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE

3' education - Nov. 25, 2019 - Binita Shah - AHA 2019, Philadelphia

Succesful repurposing of an old anti-inflammatory drug for a new application

3' education - Nov. 16, 2019 - Aruna Pradhan, MD - AHA 2019, Philadelphia

Treatment with anti-inflammatory agent reduces both first and recurrent events post-MI

3' education - Nov. 16, 2019 - Jean-Claude Tardif, MD, Canada - AHA 2019, Philadelphia

CRP levels associated with risk of cancer in stable CVD

5' education - Oct. 14, 2019 - Paris, France - Cilie van ’t Klooster, MD

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

Challenges in targeting residual risk in diabetic patients, post ACS

10' education - Sep. 25, 2019 - Prof. Peter Libby, MD

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD

Effect of IL-1β inhibition on lung cancer sheds new light on the role of inflammation

3' education - May 28, 2019 - EAS 2019, Maastricht - Paul Ridker, MD

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

Neutral study with methotrexate offers interesting insights on CV-relevant inflammatory pathway

3' education - Nov. 11, 2018

The predictive role of biomarkers in CV risk assessment

10' education - Oct. 23, 2018 - Nina Paynter, PhD - Boston, MA, USA

Understanding epigenetics: The potential rationale for BET inhibition in management of CVD

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Jorge Plutzky, MD – Boston, MA, USA

What is the situation one year after the presentation about the CANTOS trial?

10' education - Aug. 26, 2018 - Munich, Germany - Prof. Paul Ridker, MD - Boston, MA, USA

The real residual risk in patients with CVD & diabetes: The promise of epigenetics

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Erik Stroes, MD - Amsterdam, The Netherlands
Also as CME accredited e-learning

The CANTOS trial: Implications for the management of patients with residual risk

10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA - Online CME

Anti-inflammatory therapy in the prevention of cardiovascular disease

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA

No evidence that anti-inflammatory treatment prevents progression to T2DM in CANTOS trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Brendan Everett, MD - Boston, MA, USA

Anti-inflammatory treatment also gives MACE reduction in high-risk patients with kidney disease

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Paul Ridker - Boston, MA, USA
Also as CME e-learning

Inflammation & CVD: Translating insights from vascular biology to the clinic

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA - Online CME
Also as CME accredited e-learning

The new era of residual risk reduction

10' education - Nov. 16, 2017 - Prof. Erik Stroes - Amsterdam, The Netherlands - Online CME

The patient with inflammatory residual risk: Who is it?

10' education - Nov. 16, 2017 - Prof. Wolfgang Koenig - Munich, Germany - Online CME

There is hope for treatment of HFpEF

3' education - Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore

Analogous to LDL-c, the lower the better also seems true for inflammation

3' education - Nov. 14, 2017 - Paul Ridker, Boston, MA, USA

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

COVID-19 and risk of HFpEF

News - Nov. 3, 2020

This viewpoint article in JAMA reviews the latest findings on the risk of heart failure, particularly HFpEF, in those who developed acute COVID-19 and those who have recovered from the illness.

Total burden of serious CV events reduced by IL-1β inhibition

Literature - Oct. 26, 2020 - Everett BM et al. - J Am Coll Cardiol 2020

An analysis of the CANTOS trial showed that IL-1β inhibition with canakinumab reduced total number of serious CV events compared to placebo in patients with prior MI and subclinical inflammation.

Strong evidence for colchicine in patients with chronic coronary disease

5' education - Oct. 7, 2020 - Aernoud Fiolet, MD and prof. Jan Hein Cornel, MD, PhD
Investigators of the LoDoCo2 trial present the design and the major findings of this trial which evaluated colchicine in patients with chronic coronary disease.

Investigators of the LoDoCo2 trial present the design and the major findings of this trial which evaluated colchicine in patients with chronic coronary disease.

Elevated Lp(a) levels associated with increased risk of MACE when hsCRP ≥2 mg/L

Literature - July 27, 2020 - Puri R et al., - JAMA Cardiol. 2020.

Elevated Lp(a) levels were associated with greater risk of MACE in optimally treated patients with high-risk vascular disease when hsCRP levels ≥2 mg/L, but not in those with hsCRP levels <2 mg/L.

Pro-inflammatory activation of monocytes by elevated Lp(a) is reversible by potent Lp(a)-lowering

Literature - May 12, 2020 - Stiekema LCA et al., - Eur Heart J. 2020

Elevated Lp(a) contributes to pro-inflammatory gene expression of monocytes in both healthy subjects and CVD patients. Potent Lp(a)-lowering reduced the pro-inflammatory state of circulating monocytes.

High CV risk in atherosclerosis patients with highest levels of inflammatory biomarkers and LDL-c

Literature - Apr. 28, 2020 - Ridker PM, et al. - Eur Heart J 2020

Relationships between inflammation, LDL-c and CV risk have not much changed compared to findings from two decades ago. Those with highest levels of IL-6 or hsCRP and highest levels of LDL-c have highest risk of MACE.

PCSK9 siRNA does not affect inflammation measures or hematological parameters

Literature - Apr. 28, 2020 - Landmesser U et al., - Cardiovasc Res. 2020.

Inclisiran, an siRNA against PCSK9, did not result in adverse effects on measures of inflammation, immune activation and platelets. No clinical immunogenicity AEs were observed.

Higher olive oil consumption associated with lower CV and CHD risk in U.S. adults

Literature - Mar. 24, 2020 - Guasch-Ferré M et al., - J Am Coll Cardiol. 2020.

In an analysis of two large U.S. cohorts, higher olive oil intake was associated with lower risk of major CVD and CHD risk compared to those consuming olive oil <1 per month.

Coronavirus infections and the cardiovascular system

Literature - Mar. 19, 2020 - Xiong TY, et al. - Eur Heart J. 2020
This viewpoint article draws attention towards acute and possible long-term implications of coronavirus infections, such as COVID-19, on the cardiovascular system.

This viewpoint article draws attention towards acute and possible long-term implications of coronavirus infections, such as COVID-19, on the cardiovascular system.

Lp(a) and immune metabolism

5' education - Mar. 12, 2020 - EAS-endorsed Lp(a) satellite meeting - Jeffrey Kroon, PhD
Jeffrey Kroon presents his study on inflammatory mechanisms driving CV risk in patients with high Lp(a) levels and a potential new strategy to reduce atherogenesis in these patients.

Lp(a) meeting Jeffrey Kroon presents his study on inflammatory mechanisms driving CV risk in patients with high Lp(a) levels and a potential new strategy to reduce atherogenesis in these patients.

Nordic diet, similar to Mediterranean diet, may also have anti-inflammatory effects

News - Feb. 4, 2020

Several studies suggest that a healthy Nordic diet, which differs from the Mediterranean diet in that it contains berries and uses canola instead of olive oil, has beneficial effects, but the evidence is limited.

Pre-PCI P2Y12 inhibitor administration and stent-induced endothelial dysfunction and inflammation in ACS

Literature - Jan. 8, 2020 - Schnorbus B et al., - Eur Heart J. 2020

Patients with ACS who received prasugrel before PCI, showed less endothelial dysfunction and platelet aggregation, while those on clopidogrel and ticagrelor did not, nor did treatment after PCI.